In data pooled from 6 parallel-group , fixed-dose trials , efficacy appeared slightly greater at higher doses .
Treatment response appeared to vary between patient subgroups , although relative to placebo , sildenafil significantly improved erectile function in all evaluated subgroups .
In trials with parallel-group design and flexible dosing , men r and omized to receive sildenafil were less likely than those receiving placebo to drop out for any reason and no more likely to drop out due to an adverse event or laboratory abnormality .
Sildenafil was not significantly associated with serious cardiovascular events or death .
CONCLUSIONS Sildenafil improves erectile function and is generally well tolerated .
Treatment response seems to vary between patient subgroups , although sildenafil has greater efficacy than placebo in all evaluated subgroups
OBJECTIVE To determine the efficacy and safety of sildenafil citrate in the treatment of male erectile dysfunction .
Outcome analysis of goal directed therapy for impotence.
PURPOSE We assessed patient preference , satisfaction and overall outcome of goal directed management of  erectile dysfunction . MATERIAL S AND METHODS The results of goal directed therapy of impotence were assessed by an independent telephone survey of 377 consecutive men who had not received prior therapy and who were followed for a minimum of 2 years . RESULTS Patients preferred medical to surgical therapies despite significantly higher satisfaction rates achieved with surgery . Average number of treatment modalities chosen by each patient was 2 ( range 0 to 5 ) . Ultimately , only 40 % of the patients achieved a long-term satisfactory result with goal directed therapy . The remainder were not satisfied with the last treatment but chose no further therapy , were lost to followup or refused therapy from the outset . CONCLUSIONS Our results clearly demonstrate a patient preference for the least invasive forms of therapy . Patients avoid significantly more effective but also more invasive treatment options despite unsatisfactory results with less invasive methods . Future research efforts should be concentrated on the development of new medical therapies to enhance overall patient satisfaction
In data pooled from 6 parallel-group , fixed-dose trials , efficacy appeared slightly greater at higher doses .
Treatment response appeared to vary between patient subgroups , although relative to placebo , sildenafil significantly improved erectile function in all evaluated subgroups .
In trials with parallel-group design and flexible dosing , men r and omized to receive sildenafil were less likely than those receiving placebo to drop out for any reason and no more likely to drop out due to an adverse event or laboratory abnormality .
Sildenafil was not significantly associated with serious cardiovascular events or death .
CONCLUSIONS Sildenafil improves erectile function and is generally well tolerated .
Treatment response seems to vary between patient subgroups , although sildenafil has greater efficacy than placebo in all evaluated subgroups
OBJECTIVE To determine the efficacy and safety of sildenafil citrate in the treatment of male erectile dysfunction .